The Economics of Diabetes Prevention

Medical Clinics of North America

Volumn 95, Issue 2, 2011, Pages 373-384

  Herman, William H ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Cost of illness; Cost utility; Cost effectiveness; Diabetes mellitus; Glucose intolerance; Health utility

Indexed keywords

ACARBOSE; METFORMIN;

BLOOD PRESSURE; BODY MASS; COMORBIDITY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DIABETES MELLITUS; DIET THERAPY; DRUG COST; GLUCOSE INTOLERANCE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HIGH RISK POPULATION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; KINESIOTHERAPY; LIFESTYLE MODIFICATION; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK REDUCTION; STROKE; UNITED STATES;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DIET; EXERCISE; GLUCOSE INTOLERANCE; HEALTH BEHAVIOR; HEALTH EXPENDITURES; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; QUALITY OF LIFE; UNITED STATES;

EID: 79251551092     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2010.11.010     Document Type: Review

References (43)

1. Herman W.H. The economics of diabetes mellitus. Clinical diabetes mellitus: a problem-oriented approach 2000, 815-828. Thieme, New York. 3rd edition. J.K. Davidson (Ed.).
2. American Diabetes Association Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008, 31:596-615.
3. Narayan V.K., Boyle J.P., Thompson T.J., et al. Lifetime risk for diabetes mellitus in the United States. JAMA 2003, 290:1884-1890.
4. Goldman L., Cook E.F. The decline in ischemic heart disease mortality rates: an analysis of the comparative effects of medical interventions and changes in lifestyles. Ann Intern Med 1984, 101:825-836.
5. The HEALTHY Study Group A school-based intervention for diabetes risk reduction. N Engl J Med 2010, 363:443-453.
6. Pan X.R., Li G.W., Hu Y.H., et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997, 20:537-544.
7. Tuomilehto J., Lindstrom J., Eriksson J.G., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350.
8. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
9. Ramachandran A., Snehalatha C., Mary S., et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006, 49:289-297.
10. Chiasson J.L., Josse R.G., Gomis R., et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 2002, 359:2072-2077.
11. Gerstein H.C., Yusuf S., Bosch J., et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006, 368:1096-1105.
12. Nichols G.A., Glauber H.S., Brown J.B. Type 2 diabetes: incremental medical care costs during the 8 years preceding diagnosis. Diabetes Care 2000, 23:1654-1659.
13. Nichols G.A., Arondekar B., Herman W.H. Medical care costs one year after identification of hyperglycemia below the threshold for diabetes. Med Care 2008, 46:287-292.
14. Nichols G.A., Arondekar B., Herman W.H. Complications of dysglycemia and medical costs associated with nondiabetic hyperglycemia. Am J Manag Care 2008, 14:791-798.
15. Brown J.B., Pedula K.L., Bakst A.W. The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med 1999, 159:1873-1880.
16. Brandle M., Zhou H., Smith B.R., et al. The direct medical cost of type 2 diabetes mellitus. Diabetes Care 2003, 26:2300-2304.
17. Caro J.J., Ward A.J., O'Brien J.A. Lifetime costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care 2002, 25:476-481.
18. Anandacoomarasamy A., Caterson I.D., Leibman S., et al. Influence of BMI on health-related quality of life: comparison between an obese adult cohort and age-matched population norms. Obesity (Silver Spring) 2009, 17:2114-2118.
19. Sach T.H., Barton G.R., Doherty M., et al. The relationship between body mass index and health-related quality of life: comparing the EQ-5D, EuroQol VAS and SF-6D. Int J Obes 2007, 31:189-196.
20. index (health-related utility) and body mass index (obesity) in hospital-treated people with type 1 diabetes, type 2 diabetes and with no diagnosed diabetes. Diabet Med 2005, 22:1482-1486.
21. U.K. Prospective Diabetes Study Group: quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 1999, 22:1125-1136.
22. Redekop W.K., Koopmanschap M.A., Stolk R.P., et al. Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care 2002, 25:458-463.
23. Ragnarson Tennvall G., Apelqvist J. Health-related quality of life in patients with diabetes mellitus and foot ulcers. J Diabetes Complications 2000, 14:235-241.
24. Glasziou P., Alexander J., Beller E., ADVANCE Collaborative Group, et al. Which health-related quality of life score? A comparison of alternative utility measures in patients with type 2 diabetes in the ADVANCE trial. Heath Qual Life Outcomes 2007, 5:21-31.
25. Coffey J.T., Brandle M., Zhou H., et al. Valuing health-related quality of life in diabetes. Diabetes Care 2002, 25:2238-2243.
26. Herman W.H. Economic analyses of diabetes interventions: rationale, principles, findings, and interpretation. Endocrinologist 1999, 9:113-117.
27. Herman W.H., Hoerger T.J., Brandle M., et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005, 142:323-332.
28. Segal L., Dalton A.C., Richardson J. Cost-effectiveness of the primary prevention of non-insulin dependent diabetes mellitus. Health Promot Int 1998, 13:197-209.
29. Palmer A.J., Roze S., Valentine W.J., et al. Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom. Clin Ther 2004, 26:304-321.
30. Caro J.J., Getsios D., Caro I., et al. Economic evaluation of therapeutic interventions to prevent type 2 diabetes in Canada. Diabet Med 2004, 21:1229-1236.
31. Eddy D.M., Schlessinger L., Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 2005, 143:251-264.
32. Josse R.G., McGuire A.J., Saal G.B. A review of the economic evidence for acarbose in the prevention of diabetes and cardiovascular events in individuals with impaired glucose tolerance. Int J Clin Pract 2006, 60:847-855.
33. Icks A., Rathmann W., Haastert B., on behalf of the KORA Study Group, et al. Clinical and cost-effectiveness of primary prevention of type 2 diabetes in a 'real world' routine healthcare setting: model based on the KORA Survey 2000. Diabet Med 2007, 24:473-480.
34. Herman W.H., Brandle M., Zhang P., The Diabetes Prevention Program Research Group, et al. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care 2003, 26:36-47.
35. Ackermann R.T., Marrero D.G. Adapting the Diabetes Prevention Program lifestyle intervention for delivery in the community. The YMCA Model. Diabetes Educ 2007, 33:69-78.
36. Herman W.H., Brandle M., Zhang P., The Diabetes Prevention Program Research Group, et al. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care 2003, 26:2518-2523.
37. Diabetes Prevention Program Research Group 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009, 374:1677-1686.
38. Chiasson J.L., Josse R.G., Gomis R., STOP-NIDDM Trial Research Group, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003, 290:486-494.
39. Kahn S.E., Haffner S.M., Heise M.A., ADOPT Study Group, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427-2443.
40. Graham D.J., Oeullet-Hellstrom R., MaCurdy T.E., et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010, 304:411-418.
41. Wertz D.A., Chang C.L., Sarawate C.A., et al. Risk of cardiovascular events and all-cause mortality in patients treated with thiazolidinediones in a managed-care population. Circ Cardiovasc Qual Outcomes 2010, 3:538-545.
42. Li R., Zhang P., Barker L.E., et al. Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care 2010, 33:1872-1894.
43. Laupacis A., Feeny D., Detsky A.S., et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992, 146:473-481.